Strategic Funding Leverage recent €10M funding to pursue co-development and manufacturing expansion opportunities, emphasizing capacity ramp, new formulations, and international partnerships to accelerate go-to-market timelines.

Niche Ketamine Program Target opportunities around oral prolonged-release ketamine formulations for treatment-resistant depression, exploring partnerships with contract manufacturers, CROs, and pharma companies seeking specialty psychiatric products.

Swiss Manufacturing Position as a nimble Swiss pharma manufacturer with capabilities in complex formulations; craft outreach to regional and EU partners seeking high-containment production, quality systems, and scalable small- to mid-volume runs.

Tech Enablement Highlight advanced tech stack (Kubernetes, SAP, Azure, Jira, Salesforce) to reassure potential partners about modernized operations, data traceability, and efficient collaboration across development, production, and supply chain.

Financial Viability Emphasize stable revenue and funded pipeline to de-risk partnerships; present co-investment models, milestone-based payments, and risk-sharing arrangements to attract investors and licensees.